Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

DOSTARLIMAB-GXLY vs DOXORUBICIN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

DOSTARLIMAB-GXLY vs DOXORUBICIN: Safety Overview

Metric DOSTARLIMAB-GXLY DOXORUBICIN
Total FAERS Reports 504 82,754
Deaths Reported 55 15,653
Death Rate 10.9% 18.9%
Hospitalizations 126 28,630
Average Patient Age 67.4 yrs 50.5 yrs
% Female Patients 92.7% 53.9%
FDA Approval Date N/A Approved Prior to Jan 1, 1982
Manufacturer N/A Hikma Pharmaceuticals USA Inc.
Route N/A INTRAVENOUS
Marketing Status Prescription Discontinued